Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
Results of 1alpha-hydroxyvitamin D3 therapy in twelve children with renal bone disease are described. Nine of the twelve children showed a good response to 0.05--0.08 microgram/kg/day. Hypercalcaemia was the only side effect and proved easy to manage because of the short half-life of 1alpha-OHD3.
D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D002648:Child; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D004872:Ergocalciferols / Q000627:therapeutic use; D006225:Hand / Q000000981:diagnostic imaging; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D007085:Ilium / Q000473:pathology; D010758:Phosphorus / Q000097:blood; D011859:Radiography; D006435:Renal Dialysis
D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium